Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin in COVID-19 patients with elevated liver enzymes
NCT04816682Phase 4Completed
- Sponsor
- University Hospital F.D. Roosevelt
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of silymarin in coronavirus disease 2019 (COVID-19) and liver disease (2 arms), sponsored by University Hospital F.D. Roosevelt. Primary endpoints: Improvement in the COVID-19 stage of at least 1 point up to 21 days and Improvement in the activity of aminotransferases up to 21 days. Started Mar 2021; status: completed.
02
Drugs
silymarin
03
Conditions
coronavirus disease 2019 (COVID-19)liver disease
Beyond the preview
Go deeper on NCT04816682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816682.